Gyre Therapeutics Inc. Common Stock (GYRE)

FairStock Score: 34/100 — RISKY

Key Financials

Strengths

• Generates $2 million in annual free cash flow (0.3% yield on market cap)
• Conservative balance sheet with debt-to-equity of just 0.01, providing financial flexibility
• Altman Z-Score of 17.6 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 33.5% demonstrates strong top-line momentum

Concerns

• Trades significantly above Graham Number ($1) with negative 949% margin of safety—limited downside protection
• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Gyre Therapeutics Inc. Common Stock is a micro-cap healthcare company valued at $689 million. Revenue stands at $117 million, though the company is currently unprofitable. From a quality standpoint, Gyre shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and Altman Z-Score of 17.6 confirms fortress-level solvency. On valuation, the stock is commanding a steep 372.0x multiple, with trades far above its Graham Number ($1) with no margin of safety. Growth dynamics show revenue growing at 33.5% and profit growth of -1640.4%. Our composite FairStock Score of 34/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Gyre's 33% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $2 million in annual free cash flow (0.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

At 372x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer